FitzGerald, D. J., Kreitman, R., Wilson, W., Squires, D. & Pastan, I. Recombinant immunotoxins for treating cancer. Int. J. Med. Microbiol.293, 577–582 (2004). ArticleCASPubMed Google Scholar
Frankel, A. E., Neville, D. M., Bugge, T. A., Kreitman, R. J. & Leppla, S. H. Immunotoxin therapy of hematologic malignancies. Semin. Oncol.30, 545–557 (2003). ArticleCASPubMed Google Scholar
Foss, F. M., Saleh, M. N., Krueger, J. G., Nichols, J. C. & Murphy, J. R. in Clinical Applications of Immunotoxins (ed. Frankel, A. E.) 63–81 (Springer, Berlin, Germany, 1998). Book Google Scholar
Uckun, F. M. & Reaman, G. H. Immunotoxins for treatment of leukemia and lymphoma. Leuk. Lymphoma18, 195–201 (1995). ArticleCASPubMed Google Scholar
Engert, A., Sausville, E. A. & Vitetta, E. in Clinical Applications of Immunotoxins (ed. Frankel, A. E.) 13–33 (Springer, Berlin, Germany, 1998). Book Google Scholar
Naglich, J. G., Metherall, J. E., Russell, D. W. & Eidels, L. Expression cloning of a diptheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell69, 1051–1061 (1992). ArticleCASPubMed Google Scholar
Zhao, G. & London, E. Behavior of diphtheria toxin T domain containing substitutions that block normal membrane insertion at Pro345 and Leu307: control of deep membrane insertion and coupling between deep insertion of hydrophobic subdomains. Biochemistry44, 4488–4498 (2005). ArticleCASPubMed Google Scholar
Smallshaw, J. E. et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nature Biotechnol.21, 387–391 (2003). ArticleCAS Google Scholar
Gould, B. J. et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies. J. Natl Cancer Inst.81, 775–781 (1989). ArticleCASPubMed Google Scholar
Pai, L. H. et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J. Clin. Oncol.9, 2095–2103 (1991). ArticleCASPubMed Google Scholar
Pai-Scherf, L. H. et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res.5, 2311–2315 (1999). CASPubMed Google Scholar
Taniguchi, T. & Minami, Y. The IL2/IL-2 receptor system: a current overview. Cell73, 5–8 (1993). ArticleCASPubMed Google Scholar
Olsen, E. et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol.19, 376–388 (2001). ArticleCASPubMed Google Scholar
Duvic, M., Kuzel, T. M., Olsen, E. & Martin, A. G. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ontak). Clin. Lymphoma2, 222–228 (2002). ArticleCASPubMed Google Scholar
Railan, D., Fivenson, D. P. & Wittenberg, G. Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol.43, 323–324 (2000). ArticleCASPubMed Google Scholar
Foss, F. M. et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma1, 298–302 (2001). ArticleCASPubMed Google Scholar
Foss, F., Demierre, M. F. & DiVenuti, G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood106, 454–457 (2005). ArticleCASPubMed Google Scholar
Frankel, A. E. et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin. Cancer Res.9, 3555–3561 (2003). CASPubMed Google Scholar
Dang, N. H. et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol.22, 4095–4102 (2004). ArticleCASPubMed Google Scholar
Dannull, J. et al. Enhancement of vccine-mediated antitumor immunity in cancer patients: depletion of regulatory T cells. J. Clin. Invest.115, 3623–3633 (2005). ArticleCASPubMedPubMed Central Google Scholar
Uchiyama, T. A., Broder, S. & Waldmann, T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol.126, 1393–1397 (1981). CASPubMed Google Scholar
Chaudhary, V. K. et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature339, 394–397 (1989). ArticleCASPubMed Google Scholar
Kreitman, R. J. et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood94, 3340–3348 (1999). CASPubMed Google Scholar
Kreitman, R. J. et al. Phase I trial of recombinant immunotoxin anti-tac(Fv)–PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol.18, 1614–1636 (2000). Article Google Scholar
Onda, M., Kreitman, R. J., Vasmatzis, G., Lee, B. & Pastan, I. Reduction of the nonspecific toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J. Immunol.163, 6072–6077 (1999). CASPubMed Google Scholar
Onda, M. et al. Inhibition of TNFα produced by Kupffer cells protects against the non-specific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. J. Immunol.165, 7150–7156 (2000). ArticleCASPubMed Google Scholar
Schnell, R. et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia14, 129–135 (2000). ArticleCASPubMed Google Scholar
Schnell, R. et al. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5–SMPT-dgA) in Hodgkin's lymphoma. Leuk. Lymphoma30, 525–537 (1998). ArticleCASPubMed Google Scholar
Engert, A. et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5–SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood89, 403–410 (1997). CASPubMed Google Scholar
Schnell, R. et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4. dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin. Cancer Res.8, 1779–1786. (2002). CASPubMed Google Scholar
Borchmann, P., Schnell, R. & Engert, A. Immunotherapy of Hodgkin's lymphoma. Eur. J. Haematol. Suppl.66, 159–165 (2005). ArticleCAS Google Scholar
Mansfield, E., Amlot, P., Pastan, I. & FitzGerald, D. J. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood90, 2020–2026 (1997). CASPubMed Google Scholar
Kreitman, R. J., Wang, Q. C., FitzGerald, D. J. P. & Pastan, I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int. J. Cancer81, 148–155 (1999). ArticleCASPubMed Google Scholar
Kreitman, R. J. et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med.345, 241–247 (2001). ArticleCASPubMed Google Scholar
Kreitman, R. J. et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol.23, 6719–6729 (2005). ArticleCASPubMed Google Scholar
Hall, P. D., Willingham, M. C., Kreitman, R. J. & Frankel, A. E. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony stimulating factor, prolongs survival in a SCID model of acute myelogenous leukemia. Leukemia13, 629–633 (1999). ArticleCASPubMed Google Scholar
Hogge, D. E. et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood92, 589–595 (1998). CASPubMed Google Scholar
Frankel, A. E. et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia but is nontoxic to normal myeloid progenitors. Blood91, 4279–4286 (1998). Google Scholar
Frankel, A. E., Powell, B. L., Hall, P. D., Case, L. D. & Kreitman, R. J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res.8, 1004–1013 (2002). CASPubMed Google Scholar
Wescott, M. M. et al. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol. Cancer Ther.3, 1681–1689 (2004). Google Scholar
Cohen, K. A. et al. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol. Immunother.54, 799–806 (2005). ArticleCASPubMed Google Scholar
Urieto, J. O. et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr. Purif.33, 123–133 (2004). ArticleCASPubMed Google Scholar
Pastan, I. et al. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res.51, 3781–3787 (1991). CASPubMed Google Scholar
Pai, L. H., Wittes, R., Setser, A., Willingham, M. C. & Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Med.2, 350–353 (1996). ArticleCASPubMed Google Scholar
Kuan, C., Pai, L. H. & Pastan, I. Immunotoxins containing Pseudomonas exotoxin targeting LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res.1, 1589–1594 (1995). CASPubMed Google Scholar
Posey, J. A. et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin. Cancer Res.8, 3092–3099 (2002). CASPubMed Google Scholar
Chang, K. & Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl Acad. Sci. USA93, 136–140 (1996). ArticleCASPubMedPubMed Central Google Scholar
Argani, P. et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res.7, 3862–3868 (2001). CASPubMed Google Scholar
Hassan, R., Bera, T. & Pastan, I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res.10, 3937–3942 (2004). ArticleCASPubMed Google Scholar
Chowdhury, P. S., Viner, J. L., Beers, R. & Pastan, I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl Acad. Sci. USA95, 669–674 (1998). ArticleCASPubMedPubMed Central Google Scholar
Chowdhury, P. S. & Pastan I. Improving antibody affinity by mimicking somatic hypermutations in vitro. Nature Biotech.17, 568–572 (1999). ArticleCAS Google Scholar
Kreitman, R. et al. SS1(dsFv)PE38 anti-mesothelin immunotoxin in advanced malignancies: Phase I study of continous infusion. Proc. Am. Soc. Clin. Oncol.21, 22b (2002). Google Scholar
Hassan, R., Bullock, S., Kindler, H. & Pastan, I. Updated results of the phase I study of SS1(dsFv)PE38 for targeted therapy of mesothelin expressing cancers. Eur. J. Cancer2 (Suppl.), 280a (2004). Google Scholar
Garland, L. et al. Phase I trial of intravenous IL-4 Pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J. Immunother.28, 376–381 (2005). ArticleCASPubMed Google Scholar
Laske, D. W., Youle, R. J. & Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med.3, 1362–1368 (1997). ArticleCASPubMed Google Scholar
Weber, F. W. et al. in Local Therapies for Glioma: Present Status and Future Developments (eds Westphal, M., Tonn, J. C. & Ram, Z.) 93–103 (Springer, Vienna, Austria, 2003). Book Google Scholar
Rand, R. W. et al. Intratumoral administration of a recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high grade glioma. Clin. Cancer Res.6, 2157–2165 (2000). CASPubMed Google Scholar
Sampson, J. H. et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol.65, 27–35 (2003). ArticlePubMed Google Scholar
Boskovitz, A. et al. Monoclonal antibodies for brain tumour treatment. Expert Opin. Biol. Ther.4, 1453–1471 (2004). ArticleCASPubMed Google Scholar
Sampson, J. H. et al. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. J. Neuro-oncol.7, 90–96 (2005). Article Google Scholar
Parney, I. F. et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J. Neurosurg.102, 267–275 (2005). ArticleCASPubMed Google Scholar
Nagata, S. et al. Novel anti-CD30 recombinant immunotoxins containing disulphide-stabilized Fv fragments. Clin. Cancer Res.8, 2345–2355 (2002) CASPubMed Google Scholar
Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J. & Pastan, I. Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res.8, 995–1002 (2002). CASPubMed Google Scholar
Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V. & Vitetta, E. S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl Acad. Sci. USA96, 3957–3962 (1999). ArticleCASPubMedPubMed Central Google Scholar
Baluna, R., Coleman, E., Jones, C., Ghetie, V. & Vitetta, E. S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell Res.258, 417–424 (2000). ArticleCASPubMed Google Scholar
Tsutsimi, Y. et al. Site-specific chemical modification of recombinant immunotoxin anti-Tacc(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl Acad. Sci. USA97, 8548–8553 (2000). Article Google Scholar
Molineux, G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev.28, S13–S16 (2002). Article Google Scholar
Castelletti, D. et al. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin. Exp. Immunol.136, 365–372 (2004). ArticleCASPubMedPubMed Central Google Scholar
Haggerty, H. G. et al. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment. Toxicol. Pathol.27, 87–94 (1999). ArticleCASPubMed Google Scholar
Damle, B., Tay, L., Comereski, C., Warner, W. & Kaul, S. Influence of immunogenicity on the pharmacokinetics of BMS-191352, a Pseudomonas exotoxin immunoconjugate, in rats and dogs. J. Pharm. Pharmacol.52, 671–678 (2000). ArticleCASPubMed Google Scholar
Kunwar, S. in Local Therapies for Glioma: Present Status and Future Developments (eds Westphal, M., Tonn, J. C. & Ram, Z.) 105–111 (Springer, Vienna, Austria, 2003). Book Google Scholar